MA
YARW

MYDA Advisors’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

MYDA Advisors’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-26
Closed -$161K – 155
2020
Q2 		$161K Buy
+26
New +$176K 0.1% 90

Other funds holding YARW

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

MYDA Advisors's YARW Position: Q3 2020 in Review

MYDA Advisors sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q3 2020, closing a stake of 26 shares — an estimated $161K sold.

MYDA Advisors first reported a position in YARW in Q2 2020 and held it in 1 quarter. The position peaked at $161K in Q2 2020. 97 funds tracked by Wall St. Rank hold YARW as of Q3 2020.

  • MYDA Advisors reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • MYDA Advisors sold 26 Yarrow Bioscience, Inc. Common Stock shares in Q3 2020, an estimated $161K.
  • MYDA Advisors first reported a position in Yarrow Bioscience, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • MYDA Advisors's Yarrow Bioscience, Inc. Common Stock position peaked at $161K in Q2 2020.
  • 97 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q3 2020.

Based on MYDA Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.